Double Blinded Phase(이중 맹검 단계)란 무엇입니까?
Double Blinded Phase 이중 맹검 단계 - MATERIALS AND METHODS The original trial (E2805) is a randomized, double-blinded phase 3 clinical trial comparing outcomes in 1,943 patients with RCC accrued between 2006 and 2010, and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib. [1] As per the sponsor's decision, the study was terminated after the phase I part, as the clinical efficacy of the combination is currently being investigated in a pivotal, placebo-controlled (PEM mono), double-blinded phase III trial (STARBOARD,NCT04657991). [2] The study is a randomized, controlled, double-blinded phase IV clinical trial. [3] The results of JUPITER-02, a randomized, placebo-controlled, double-blinded Phase III trial of toripalimab in combination with GP chemotherapy as first-line treatment for r/m NPC are summarized. [4] We sought to determine the efficacy of retapamulin as a topical decolonizing agent against mupirocin-resistant MRSA among the identified high-risk Brooklyn cluster via a randomized, placebo-controlled, double-blinded phase three trial. [5] METHODS BARDA conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10-12 years administered with or without MF59® adjuvant, stored over the previous 2-7 years at the time of vaccination. [6] MethodsThis randomised, placebo-controlled, double-blinded phase IIb clinical trial compares the improvement on ventricular function (measured by the changes on the ejection fraction) of patients receiving the conventional treatment for DC in combination with a single dose of an intracoronary infusion of BMMNCs, with the functional recovery of patients receiving placebo plus conventional treatment. [7] METHODS In this double-blinded phase 2b study, adults with acute uncomplicated influenza A were randomized 1:1:1:1 to receive one of the following treatments twice daily for 5 days: placebo, pimodivir 300 mg or 600 mg, or pimodivir 600 mg plus oseltamivir 75 mg. [8]재료 및 방법 원래 시험(E2805)은 2006년에서 2010년 사이에 발생한 RCC 환자 1,943명의 결과를 비교하고 최대 1년의 보조 위약, 수니티닙 또는 소라페닙으로 치료한 결과를 비교한 무작위 이중 맹검 3상 임상 시험입니다. [1] 후원자의 결정에 따라 연구는 현재 중추, 위약 대조(PEM 모노), 이중 맹검 3상 시험(STARBOARD, NCT04657991)에서 조합의 임상 효능이 조사되고 있기 때문에 1상 부분 이후에 종료되었습니다. . [2] 이 연구는 무작위, 대조, 이중 맹검 IV상 임상 시험입니다. [3] r/m NPC에 대한 1차 치료로서 GP 화학요법과 토리팔리맙을 병용한 무작위, 위약 대조, 이중 맹검 3상 시험인 JUPITER-02의 결과가 요약되어 있습니다. [4] nan [5] nan [6] nan [7] nan [8]